Related Experiment Video
Updated: Apr 22, 2026
A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes
Published on: April 11, 2025
Immunosuppressive factor blockade in dendritic cells via siRNAs results in objective clinical responses
Mouldy Sioud1, Anne Mobergslien, Stein Sæbøe-Larssen
1Department of Immunology, Institute for Cancer Research, Oslo University Radium Hospital, Norway, 0310, Montebello, Oslo, Norway, mouldy.sioud@rr-research.no.
Abstract:
Over the past decade, immunotherapy has emerged as a promising new form of cancer treatment with the potential to eradicate tumor metastasis. However, its curative potential is in general limited by the existence of negative feedback mechanisms that control dendritic cells (DCs) and T-cell activation. For clinically effective immunity, there is a need of inhibiting the expression of these immune suppressors. This could enhance the activation of DCs, T cells, and natural killer cells, and might be beneficial for cancer immunotherapy. Among the immune inhibitory molecules expressed by DCs is indoleamine 2,3-dioxygenase (IDO), an enzyme that conveys immunosuppressive effects by degrading tryptophan, an essential amino acid required for T-cell proliferation and survival. Depletion of tryptophan by IDO-positive DCs induces T-cell apoptosis and the conversion of naïve CD4+ T cells into regulatory T cells that further suppress antitumor immunity. Herein, we describe a protocol for in vitro synthesis of small interfering RNA against IDO and other immunosuppressive factors such as interleukin-10 and programmed cell death-1 ligands in order to reverse immune suppression mediated by DCs. Vaccination with IDO-silenced DC vaccines enhanced immune responses and antitumor immunity in cancer patients.
Insights
Immunotherapy for cancer faces challenges from immune suppressors. Silencing indoleamine 2,3-dioxygenase (IDO) in dendritic cells (DCs) can enhance anti-tumor immunity in patients.
Area of Science:
- Immunology
- Cancer Research
- Molecular Biology
Background:
- Immunotherapy shows promise for cancer treatment, but its effectiveness is often limited by negative feedback mechanisms controlling immune responses.
- Dendritic cells (DCs) express immune suppressive molecules, such as indoleamine 2,3-dioxygenase (IDO), which degrade tryptophan, hindering T-cell activation and promoting tumor metastasis.
- Overcoming DC-mediated immune suppression is crucial for developing effective cancer immunotherapies.
Purpose of the Study:
- To develop a method for inhibiting immune suppressive factors expressed by DCs, specifically IDO, interleukin-10, and programmed cell death-1 ligands.
- To investigate the potential of using small interfering RNA (siRNA) to silence these immunosuppressive molecules in DCs.
- To evaluate the impact of IDO-silenced DC vaccines on immune responses and anti-tumor immunity in cancer patients.
Main Methods:
- In vitro synthesis of small interfering RNA (siRNA) targeting indoleamine 2,3-dioxygenase (IDO), interleukin-10, and programmed cell death-1 ligands.
- Development of a protocol for silencing these immunosuppressive factors in dendritic cells (DCs).
- Vaccination of cancer patients with DCs engineered to express reduced levels of IDO and other suppressive factors.
Main Results:
- The described protocol successfully synthesized siRNA against IDO and other immunosuppressive factors.
- Silencing of IDO in DCs reversed immune suppression mediated by these cells.
- Vaccination with IDO-silenced DC vaccines led to enhanced immune responses and improved anti-tumor immunity in cancer patients.
Conclusions:
- Targeting and silencing immunosuppressive molecules like IDO in DCs is a viable strategy to enhance anti-tumor immunity.
- IDO-silenced DC vaccines represent a promising approach for improving cancer immunotherapy outcomes.
- Further research into DC-based immunotherapy holds potential for overcoming cancer metastasis.
